A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors

• Status: Completed
• Trial end date: 2018-07-26
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to confirm the safety and efficacy of sunitinib in subjects with unresectable pancreatic neuroendocrine tumors.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Sunitinib

Criteria

Inclusion Criteria:

• Histologically or cytologically proven diagnosis of well-differentiated pancreatic neuroendocrine tumor (according to World Health Organization [WHO 2000] classification).

• Disease progression within 12 months prior to study enrollment.

• Disease that is not amenable to surgery, radiation, or combined modality therapy with curative intent.

Exclusion Criteria:

• Patients with poorly differentiated pancreatic neuroendocrine tumors (according to WHO 2000 classification).

• Prior treatment with any tyrosine kinase inhibitors, anti vascular endothelial growth factor (VEGF) angiogenesis inhibitors, non VEGF targeted angiogenesis inhibitors, or mammalian target of rapamycin (mTOR) inhibitors.